Células madre mesenquimales haploidénticas derivadas de médula ósea (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-000606-37-ES (EUCTR) | 16/11/2017 | 18/09/2017 | Safety study of mesenchymal stem cells in the treatment of Recessive Dystrophic Epidermolysis Bullosa. | Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. | Recessive Dystrophic Epidermolysis Bullosa;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Mesenchymal Stem Cells extracted from bone marrow INN or Proposed INN: Células madre mesenquimales haploidénticas derivadas de médula ósea Other descriptive name: MESENCHYMAL STEM CELLS (MSCS) | Fundación para la Investigación Biomédica Hospital Universitario La Paz | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 9 | Phase 1 | Spain |